|
Neoplasms
|
0.060 |
AlteredExpression
|
group |
BEFREE |
The results of the present study confirmed the constitutive expression of CYP2S1 and CYP2W1 in breast cancer cells, although their relatively low level of expression suggests that they may be less involved in the transformation of therapeutic agents in these types of tumors.
|
31561186 |
2019 |
|
Malignant Neoplasms
|
0.060 |
GeneticVariation
|
group |
BEFREE |
The correlation of genetic polymorphisms of CYP2W1 and cancer risk was uncertain.5.
|
27690753 |
2017 |
|
Colorectal Carcinoma
|
0.060 |
Biomarker
|
disease |
BEFREE |
CYP2W1 expression level was suggested to serve as an independent prognostic biomarker in colorectal cancer and hepatocellular carcinoma.
|
27690753 |
2017 |
|
Primary malignant neoplasm
|
0.060 |
GeneticVariation
|
group |
BEFREE |
The correlation of genetic polymorphisms of CYP2W1 and cancer risk was uncertain.5.
|
27690753 |
2017 |
|
Malignant Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
Cytochrome P450 2W1 (CYP2W1) is a colon tumor-specific enzyme, suggested as a potential target for cancer therapy.
|
26787547 |
2016 |
|
Colonic Neoplasms
|
0.060 |
AlteredExpression
|
group |
BEFREE |
Human cytochome P450 2W1 (CYP2W1) enzyme is expressed in fetal colon and in colon tumors.
|
27598485 |
2016 |
|
Colonic Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
Indolines constitute high affinity exogenous compounds and specific chloromethylindolines have been shown to be activated by CYP2W1 into cytotoxic products in vitro and also in vivo, inhibiting the growth of human colon tumors in a mouse xenograft model.
|
27257736 |
2016 |
|
Colonic Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
Cytochrome P450 2W1 (CYP2W1) is a colon tumor-specific enzyme, suggested as a potential target for cancer therapy.
|
26787547 |
2016 |
|
Colorectal Carcinoma
|
0.060 |
Biomarker
|
disease |
BEFREE |
The CRC specific localization of CYP2W1 and its effective prodrug activation makes it a very promising target for future development of cancer therapeutics.
|
27257736 |
2016 |
|
Neoplasms
|
0.060 |
AlteredExpression
|
group |
BEFREE |
However, significant CYP2W1 protein expression was found in only one tumor sample (a testosterone-producing adrenocortical carcinoma) and not in any normal tissue.
|
27598485 |
2016 |
|
Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
However, the role of CYP2W1 in the endogenous and tumor localized metabolism of retinol derivatives has yet to be clarified.
|
27257736 |
2016 |
|
Primary malignant neoplasm
|
0.060 |
Biomarker
|
group |
BEFREE |
Cytochrome P450 2W1 (CYP2W1) is a colon tumor-specific enzyme, suggested as a potential target for cancer therapy.
|
26787547 |
2016 |
|
Colonic Neoplasms
|
0.060 |
AlteredExpression
|
group |
BEFREE |
Developmental regulation and induction of cytochrome P450 2W1, an enzyme expressed in colon tumors.
|
25844926 |
2015 |
|
Colorectal Carcinoma
|
0.060 |
Biomarker
|
disease |
BEFREE |
CYP2W1 has been proposed as an attractive target for colorectal cancer (CRC) therapy by exploiting its ability to activate duocarmycin prodrugs to cytotoxic metabolites.
|
25844926 |
2015 |
|
Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
The imatinib mediated induction of CYP2W1 suggests an adjuvant therapy to treatment with duocarmycins that thus would involve induction of tumor CYP2W1 levels followed by the CYP2W1 activated duocarmycin prodrugs.
|
25844926 |
2015 |
|
Neoplasms
|
0.060 |
AlteredExpression
|
group |
BEFREE |
In addition, CYP2W1 expression was significantly correlated with tumor size (P = 0.023), histological differentiation (P = 0.04), and tumor stage (P = 0.014).
|
24801906 |
2014 |
|
Colorectal Carcinoma
|
0.060 |
GeneticVariation
|
disease |
BEFREE |
These epidemiological data obtained from a large population of CRC patients and controls cannot confirm the previously suggested decreased risk for CRC among carriers of CYP2W1*2.
|
24088132 |
2013 |
|
Malignant Neoplasms
|
0.060 |
AlteredExpression
|
group |
BEFREE |
The analysis of colorectal normal and cancer tissues and CYP2W1 overexpressing human embryonic kidney (HEK) 293 cells showed that a fraction of CYP2W1 is modified by N-glycosylation.
|
20805301 |
2010 |
|
Colorectal Carcinoma
|
0.060 |
Biomarker
|
disease |
BEFREE |
Colorectal cancer-specific cytochrome P450 2W1: intracellular localization, glycosylation, and catalytic activity.
|
20805301 |
2010 |
|
Colorectal Carcinoma
|
0.060 |
GeneticVariation
|
disease |
BEFREE |
CYP2W1 variant alleles in Caucasians and association of the CYP2W1 G541A (Ala181Thr) polymorphism with increased colorectal cancer risk.
|
20602611 |
2010 |
|
Primary malignant neoplasm
|
0.060 |
AlteredExpression
|
group |
BEFREE |
The analysis of colorectal normal and cancer tissues and CYP2W1 overexpressing human embryonic kidney (HEK) 293 cells showed that a fraction of CYP2W1 is modified by N-glycosylation.
|
20805301 |
2010 |
|
Malignant Neoplasms
|
0.060 |
AlteredExpression
|
group |
BEFREE |
CYP2W1 is a novel enzyme shown to be selectively expressed in rat fetal colon and in human colon cancer and has previously been suggested as a potential drug target for cancer therapy.
|
17979506 |
2007 |
|
Malignant Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
The selective expression in some forms of cancers and the low expression in normal tissues render CYP2W1 as a possible drug target during cancer therapy.
|
17150034 |
2007 |
|
Colonic Neoplasms
|
0.060 |
AlteredExpression
|
group |
BEFREE |
The expression of CYP2W1 is colon tumor-specific and is associated with methylation status of the CYP2W1 gene, suggesting a potential causal link between the gene hypomethylation and its enhanced expression.
|
17979506 |
2007 |
|
Neoplasms
|
0.060 |
AlteredExpression
|
group |
BEFREE |
Methylation analysis of the CpG island in the exon 1-intron 1 junction of the CYP2W1 gene from both cell lines, tumors and normal tissues revealed that demethylated CpG dinucleotides appeared as a requirement for high CYP2W1 gene expression.
|
17979506 |
2007 |